Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.

出版年份 2014 全文链接

标题

作者

关键词

出版物

Volume 73, Issue 8 Supplement, Pages LB-64-LB-64

出版商

American Association for Cancer Research (AACR)

发表日期

2014-08-15

DOI

10.1158/1538-7445.am2013-lb-64

Discuss science. Find collaborators. Network.

Join a conversation

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started